ArticleCureus2026
Incidental Detection With 18F-PSMA (Prostate-Specific Membrane Antigen)-1007 PET/CT of Multifocal Papillary Thyroid Carcinoma During Staging of Very High-Risk Prostate Adenocarcinoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has become increasingly integrated into prostate cancer staging and restaging. PSMA expression, however, is not restricted to prostatic tissue and may be detected in several non-prostatic malignancies, including thyroid carcinoma. We report the case of a male patient with very high-risk acinar prostate adenocarcinoma (Gleason score 4+4) who underwent whole-body 18F-PSMA-1007 PET/CT for staging purposes. The patient was classified as very high-risk according to NCCN (National Comprehensive Cancer Network) criteria and was managed with androgen deprivation therapy, radiotherapy, and salvage radical prostatectomy. Imaging demonstrated a focal PSMA-avid hypodense nodule in the right thyroid lobe, measuring 15 mm with a maximum standardized uptake value (SUVmax) of 6.33. Subsequent neck ultrasonography (TI-RADS 4) and fine-needle aspiration biopsy confirmed papillary thyroid carcinoma (Bethesda category VI). The patient underwent a total thyroidectomy with a level VI central neck dissection. Histopathological examination revealed multifocal papillary thyroid carcinoma with focal vascular invasion involving three vessels and central compartment nodal metastasis (pT1bN1a). Following surgery and radioactive iodine ablation with 150 mCi of iodine-131, the patient achieved an excellent biochemical response, with thyroglobulin becoming undetectable under TSH (thyroid-stimulating hormone) suppression and no evidence of structural recurrence on follow-up imaging. This case highlights the clinical relevance of incidental focal thyroid uptake detected on PSMA PET/CT performed for prostate cancer staging. Incidental PSMA-avid thyroid lesions may occasionally identify biologically significant synchronous malignancies and should prompt dedicated evaluation with ultrasonography and fine-needle aspiration when clinically appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.